Abstract
Background. The prevention of oral mucositis (OM) in the management of hematological malignancies continues to represent an unmet clinical need. Addressing this issue has major clinical implications as OM can also greatly impair patient’s quality of life. Objectives. To review currently available measures and investigational agents to prevent OM in hematological patients. Methods: we searched for OM and related issues using Medline; the abstract books of the most important hematological and oncological meetings were also reviewed. Results/Conclusions. Many agents targeting different mechanisms of mucosal damage have been applied in order to prevent OM; most of them have failed or its efficacy has not been fully demonstrated. Palifermin is the first pharmaceutical/biological agent approved for the prevention of OM; its use is currently restricted to patients who have received radiotherapy-containing conditioning regimens prior to autologous hematopoietic stem cell transplantation. No clear benefit by this agent has been demonstrated outside of this specific setting and its application should be limited to clinical trials. Other interventions, such as other growth factors and non mitogenic measures are under investigation or in development and their application in the hematological setting is expected in the short term.
Keywords: Antineoplastic treatments, chemotherapy, hematology, hematopoietic stem cell transplantation, Lactobacillus brevis CD2, leukemia, lymphoma, multiple myeloma, mucositis, oral cavity, palifermin, prevention, radiotherapy, stomatitis
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
Volume: 10 Issue: 4
Author(s): Pasquale Niscola, Andrea Tendas, Luca Cupelli, Gianfranco Catalano, Laura Scaramucci, Marco Giovannini, Vito Trinchieri, Atul Sharma, Fabio Efficace, Claudio Cartoni, Daniela Piccioni, Alessio Perrotti, Teresa Dentamaro, Paolo de Fabritiis and Dorothy M.K. Keefe
Affiliation:
Keywords: Antineoplastic treatments, chemotherapy, hematology, hematopoietic stem cell transplantation, Lactobacillus brevis CD2, leukemia, lymphoma, multiple myeloma, mucositis, oral cavity, palifermin, prevention, radiotherapy, stomatitis
Abstract: Background. The prevention of oral mucositis (OM) in the management of hematological malignancies continues to represent an unmet clinical need. Addressing this issue has major clinical implications as OM can also greatly impair patient’s quality of life. Objectives. To review currently available measures and investigational agents to prevent OM in hematological patients. Methods: we searched for OM and related issues using Medline; the abstract books of the most important hematological and oncological meetings were also reviewed. Results/Conclusions. Many agents targeting different mechanisms of mucosal damage have been applied in order to prevent OM; most of them have failed or its efficacy has not been fully demonstrated. Palifermin is the first pharmaceutical/biological agent approved for the prevention of OM; its use is currently restricted to patients who have received radiotherapy-containing conditioning regimens prior to autologous hematopoietic stem cell transplantation. No clear benefit by this agent has been demonstrated outside of this specific setting and its application should be limited to clinical trials. Other interventions, such as other growth factors and non mitogenic measures are under investigation or in development and their application in the hematological setting is expected in the short term.
Export Options
About this article
Cite this article as:
Niscola Pasquale, Tendas Andrea, Cupelli Luca, Catalano Gianfranco, Scaramucci Laura, Giovannini Marco, Trinchieri Vito, Sharma Atul, Efficace Fabio, Cartoni Claudio, Piccioni Daniela, Perrotti Alessio, Dentamaro Teresa, de Fabritiis Paolo and M.K. Keefe Dorothy, The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (4) . https://dx.doi.org/10.2174/187152512803530324
DOI https://dx.doi.org/10.2174/187152512803530324 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Using Insights into Pim1 Structure to Design New Anticancer Drugs
Current Pharmaceutical Design Macromolecular and Nanotechnological Modification of Camptothecin and its Analogs to Improve the Efficacy
Current Drug Discovery Technologies From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers
Current Medicinal Chemistry Immunomodulation Via Targeted Inhibition of Antigen Receptor Signal Transduction
Cardiovascular & Hematological Disorders-Drug Targets RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Copper Homeostasis for the Developmental Progression of Intraerythrocytic Malarial Parasite
Current Topics in Medicinal Chemistry Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Diagnosis and Treatment of Pulmonary Fungal Infections in Critically Ill Patients
Current Respiratory Medicine Reviews DNA Polymerases as Targets of Anticancer Nucleosides
Current Drug Targets Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia
Current Molecular Medicine Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents Recent Synthetic Strategies for Monocyclic Azole Nucleus and Its Role in Drug Discovery and Development
Current Organic Synthesis An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy